Pancreatic Cancer Research

ResearcherUniversity of Yamanashi HospitalNo recent work listed

Hideki Fujii

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1438-3690; OpenAlex author ID A5102937647. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 4

  1. Predictors of the therapeutic effect of Nab-paclitaxel plus gemcitabine therapy for patients with recurrent pancreatic cancer after pancreatectomy Co-author DOI 10.21203/rs.3.rs-3201226/v1↗
  2. Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13019↗
  3. Tyrosine Phosphorylation of Focal Adhesion Anchoring Proteins Enhances Human Pancreatic Cancer Cell Invasion. Last author DOI 10.1097/mpa.0000000000000629↗
  4. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma]. First author PMID 25857011↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromichi Kawaida · 3 shared papers, 2015–2023 · strength 0.31
  2. Hiroshi Kono · 2 shared papers, 2018–2023 · strength 0.20
  3. Shinichi Takano · 2 shared papers, 2018–2023 · strength 0.20
  4. Daisuke Ichikawa · 2 shared papers, 2018–2023 · strength 0.20
  5. Satoshi Kawakami · 1 shared paper, 2023 · strength 0.14
  6. Ryo Saito · 1 shared paper, 2023 · strength 0.14
  7. Nobuyuki Enomoto · 1 shared paper, 2023 · strength 0.14
  8. Hirotaka Okamoto · 1 shared paper, 2016 · strength 0.10
  9. Shintaro Ichikawa · 1 shared paper, 2018 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.